ReviewJournal of inflammation research2026
Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 (T2) inflammation is a major pathogenic pathway in asthma and a clinically relevant endotype in a subgroup of patients with chronic obstructive pulmonary disease (COPD). This narrative review compares the mechanisms, biomarker-based assessment, and targeted treatment of T2 inflammation across these diseases. We focus on blood and sputum eosinophils, fractional exhaled nitric oxide (FeNO), and total and allergen-specific immunoglobulin E (IgE), while examining discordance among biomarkers and the effects of corticosteroids, smoking, infection, circadian variation, coexisting T2 diseases, and population- or assay-dependent thresholds. We distinguish the adjunctive role of biomarkers in diagnosis from their more established roles in phenotyping, risk stratification, and treatment selection. Evidence from pivotal trials is synthesized for established and recently approved therapies, including the jurisdiction-specific positioning of depemokimab in severe asthma and mepolizumab in eosinophilic COPD, while investigational strategies targeting epithelial alarmins and related pathways are critically appraised. We also discuss clinical remission as an evolving treatment goal. Overall, repeated multidimensional assessment integrating biomarkers with clinical characteristics, lung function, comorbidities, exacerbation history, and treatment exposure is more informative than any single threshold and may support more precise management of asthma and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.